QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostic technologies for point-of-care settings, clinical labs, and transfusion medicine, announced the appointment of John R. Chiminski and R. Scott Huennekens to its board of directors, effective December 6, 2024. These appointments underscore QuidelOrtho’s dedication to maintaining a strong, independent Board with diverse expertise and experience. The appointments follow a thorough search led by the Board’s Nominating and Corporate Governance Committee with the assistance of an independent executive search firm.
Kenneth F. Buechler, Ph.D., Chairman of the Board, expressed enthusiasm about the new members, stating, “We are excited to welcome John and Scott to our Board. They bring proven track records of growth and value creation as CEOs and board members of healthcare, biopharma, and MedTech companies. We are confident they will add tremendous value as we work with management to execute QuidelOrtho’s growth and transformation plans and further enhance shareholder value.”
Brian J. Blaser, President and CEO of QuidelOrtho, also expressed his excitement, noting that Chiminski and Huennekens bring valuable global experience and diverse expertise that will support the company’s transformational strategy. “I look forward to benefiting from their guidance and partnership as we continue to drive innovation in diagnostic testing and improve patient outcomes.”
Chiminski has a distinguished background in medical diagnostics and pharmaceuticals, with experience in operations leadership, product development, and global business growth. He served as CEO of Catalent (NYSE: CTLT) from 2009 to 2022 and became Chair of its Board in 2016. Chiminski played a pivotal role in Catalent’s transformation into a biopharma services leader following its spin-off from Cardinal Health. Before Catalent, Chiminski spent over 20 years at GE Healthcare, ultimately serving as President and CEO of GE Medical Diagnostics, overseeing $1.9 billion in sales.
Huennekens is a seasoned MedTech executive with experience as CEO, Chair, and board member. He served as President and CEO of Volcano Corporation, a leader in minimally invasive therapy guidance for interventional cardiology, and as Chair, President, and CEO of Verb Surgical, a surgical technology startup formed by Google and Johnson & Johnson. Huennekens has been involved in over 20 startups and public companies and currently serves as Chair of the board at Envista Holdings (NYSE: NVST) and Hyperfine (Nasdaq: HYPR).
These new appointments follow the recent resignations of James R. Prutow and Robert R. Schmidt from the Board, effective November 21, 2024, after the secondary offering of QuidelOrtho common stock by The Carlyle Group. With the addition of Chiminski and Huennekens, the Board now consists of 11 directors, 10 of whom are independent.
Dr. Buechler also acknowledged the contributions of Prutow and Schmidt, expressing gratitude for their service to the company.
QuidelOrtho remains dedicated to advancing diagnostics and improving healthcare outcomes globally. For more information, visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook, and X.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in-vitro diagnostics, offering intelligent solutions that transform data into actionable insights. The company provides expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, delivering fast, accurate, and reliable diagnostics when and where needed. QuidelOrtho is committed to advancing healthcare by partnering with customers across the global healthcare continuum.
